Longitudinal tau and metabolic PET imaging in relation to novel CSF tau measures in Alzheimer’s disease
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
Studies comparing CSF and PET tau biomarkers have included only commercial CSF assays examining specific phosphorylation sites (e.g. threonine 181, P-tau 181p ) and mid-domain tau (i.e. total tau, T-tau). Moreover, these studies did not examine CSF tau levels in relation to cerebral glucose metabolism. We thus aimed to examine CSF tau measures, using both commercial and novel assays, in relation to [ 18 F]THK5317 (tau) and [ 18 F]FDG PET (glucose metabolism). Fourteen Alzheimer’s disease (AD) patients (seven prodromal, seven dementia) underwent [ 18 F]THK5317 and [ 18 F]FDG PET studies, with follow-up performed in ten subjects (six prodromal, four dementia) after 17 months. In addition to commercial assays, novel measures capturing N-terminus+mid-domain (tau N-Mid) and C-terminally truncated (tau-368) fragments were included. While the levels of all forms of CSF tau were found to be inversely associated with baseline [ 18 F]FDG uptake, associations with baseline [ 18 F]THK5317 uptake varied in relation to the degree of isocortical hypometabolism ([ 18 F]FDG SUVR). Changes in the levels of the novel CSF markers tracked longitudinal changes in tracer uptake better than changes in P-tau 181p and T-tau levels, and improved concordance with dichotomized regional [ 18 F]THK5317 measures. Our findings suggest that neurodegeneration may modulate the relationship between CSF and PET tau biomarkers, and that, by comparison to P-tau 181p and T-tau, tau-368 and tau N-Mid may better capture tau pathology and synaptic impairment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria
Dubois, B., Feldman, H. H., Jacova, C., Hampel, H., Molinuevo, J. L., Blennow, K., DeKosky, S. T., Gauthier, S., Selkoe, D., Bateman, R., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70090-0 · Cited by 3,321
Self-citationA/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Feldman, H. H., Frisoni, G. B., Hampel, H., Jagust, W. J., Johnson, K. A., Knopman, D. S., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000002923 · Cited by 1,864
Self-citationCerebrospinal fluid and plasma biomarkers in Alzheimer disease
Blennow, K., Hampel, H., Weiner, M., & Zetterberg, H. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.4 · Cited by 1,863 · cited 1×
“the formation of neurofibrillary tangle (NFT) pathology, and total tau (T-tau), that reflects the intensity of axonal and neuronal damage [1].”
Self-citationCSF markers for incipient Alzheimer's disease
Blennow, K., & Hampel, H. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00530-1 · Cited by 1,291 · cited 1×
“disease process) and a stage marker (reflecting the cumulative extent of the degenerative process) [45].”
Self-citationTau pathology and neurodegeneration
Spillantini, M. G., & Goedert, M. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70090-5 · Cited by 1,133
Use of Florbetapir-PET for Imaging β-Amyloid Pathology
Clark, C. M. (2011) · JAMA · doi:10.1001/jama.2010.2008 · Cited by 1,117
Blennow, K., Wallin, A., Ågren, H., Spenger, C., Siegfried, J., & Vanmechelen, E. (1995) · Molecular and Chemical Neuropathology · doi:10.1007/bf02815140 · Cited by 789
Self-citationEarly clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807
Chien, D. T., Bahri, S., Szardenings, A. K., Walsh, J. C., Mu, F., Su, M.-Y., Shankle, W. R., Elizarov, A., & Kolb, H. C. (2013) · Journal of Alzheimer's Disease · doi:10.3233/jad-122059 · Cited by 651 · cited 1×
“One such ligand is [(18)F]flortaucipir (formerly known as [(18)F]T-807 and [(18)F]AV1451) [2, 3], and studies examining the relationship between [(18)F]flortaucipir uptake and CSF tau levels have shown modest positive correlations in cognitively unim-”
Background[ 18 F]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease
Xia, C., Arteaga, J., Chen, G., Gangadharmath, U., Gomez, L. F., Kasi, D., Lam, C., Liang, Q., Liu, C., Mocharla, V. P., et al. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.11.008 · Cited by 605
Tau Kinetics in Neurons and the Human Central Nervous System
Sato, C., Barthélemy, N. R., Mawuenyega, K. G., Patterson, B. W., Gordon, B. A., Jockel-Balsarotti, J., Sullivan, M., Crisp, M. J., Kasten, T., Kirmess, K. M., et al. (2018) · Neuron · doi:10.1016/j.neuron.2018.02.015 · Cited by 586 · cited 1×
“Indeed, several studies, including recent work using stable isotope labelling kinetics (SILK) to monitor the half-life and turnover rate of tau [35], have shown that, following an initial increase, CSF tau levels decrease in patients with symptomatic AD [15, 16, 36–38].”
Zhang, Z., Song, M., Liu, X., Kang, S. S., Kwon, I.-S., Duong, D. M., Seyfried, N. T., Hu, W. T., Liu, Z., Wang, J.-Z., et al. (2014) · Nature Medicine · doi:10.1038/nm.3700 · Cited by 494
Self-citationRelationships between biomarkers in aging and dementia
Jagust, W. J., Landau, S. M., Shaw, L. M., Trojanowski, J. Q., Koeppe, R. A., Reiman, E. M., Foster, N. L., Petersen, R. C., Weiner, M. W., Price, J. C., et al. (2009) · Neurology · doi:10.1212/wnl.0b013e3181bc010c · Cited by 456 · cited 1×
“Previous studies addressing the relationship between crosssectional [(18)F]FDG uptake and CSF tau levels (P-tau181p and T-tau) in patients with AD have shown mixed results: although all have shown an inverse association, some have shown no significant association [39], significant associations only for P-tau181p [40]…”
Longitudinal Change in CSF Biomarkers in Autosomal-Dominant Alzheimer’s Disease
Fagan, A. M., Xiong, C., Jasielec, M. S., Bateman, R. J., Goate, A. M., Benzinger, T. L. S., Ghetti, B., Martins, R. N., Masters, C. L., Mayeux, R., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007901 · Cited by 434 · cited 2×
“Possibly, the isolated [(18)F]THK5317 positivity may reflect a deceleration in neurodegeneration and/or the spread of NFT pathology, as previously described [16, 37].”
Longitudinal cognitive and biomarker changes in dominantly inherited Alzheimer disease
McDade, E., Wang, G., Gordon, B. A., Hassenstab, J., Benzinger, T. L. S., Buckles, V., Fagan, A. M., Holtzman, D. M., Cairns, N. J., Goate, A. M., et al. (2018) · Neurology · doi:10.1212/wnl.0000000000006277 · Cited by 314 · cited 1×
“Possibly, the isolated [(18)F]THK5317 positivity may reflect a deceleration in neurodegeneration and/or the spread of NFT pathology, as previously described [16, 37].”
Mattsson, N., Insel, P. S., Donohue, M., Landau, S., Jagust, W. J., Shaw, L. M., Trojanowski, J. Q., Zetterberg, H., Blennow, K., & Weiner, M. W. (2015) · Brain · doi:10.1093/brain/awu367 · Cited by 237
Self-citationCharacterization of Novel CSF Tau and ptau Biomarkers for Alzheimer’s Disease
Meredith Jr., J. E., Sankaranarayanan, S., Guss, V., Lanzetti, A. J., Berisha, F., Neely, R. J., Slemmon, J. R., Portelius, E., Zetterberg, H., Blennow, K., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0076523 · Cited by 209
Self-citationGordon, B. A., Friedrichsen, K., Brier, M., Blazey, T., Su, Y., Christensen, J., Aldea, P., McConathy, J., Holtzman, D. M., Cairns, N. J., et al. (2016) · Brain · doi:10.1093/brain/aww139 · Cited by 184
Longitudinal change in CSF Tau and Aβ biomarkers for up to 48 months in ADNI
Toledo, J. B., Xie, S. X., Trojanowski, J. Q., & Shaw, L. M. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1151-4 · Cited by 180 · cited 1×
“Given findings suggesting that disease progression may be accompanied by a reduction in CSF tau [15, 16], it was hypothesized that the degree of glucose hypometabolism may modulate associations between CSF tau levels and [(18)F]THK5317 uptake.”
BackgroundCorrelations of 18F-THK5351 PET with Postmortem Burden of Tau and Astrogliosis in Alzheimer Disease
Harada, R., Ishiki, A., Kai, H., Sato, N., Furukawa, K., Furumoto, S., Tago, T., Tomita, N., Watanuki, S., Hiraoka, K., et al. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.197426 · Cited by 168
Sutphen, C. L., McCue, L., Herries, E. M., Xiong, C., Ladenson, J. H., Holtzman, D. M., Fagan, A. M., & On behalf of, A. D. N. I. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.01.012 · Cited by 162
Förster, S., Grimmer, T., Miederer, I., Henriksen, G., Yousefi, B. H., Graner, P., Wester, H.-J., Förstl, H., Kurz, A., Dickerson, B. C., et al. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.04.023 · Cited by 119
Cited by
Fernández-Calle, R., Konings, S. C., Frontiñán-Rubio, J., García-Revilla, J., Camprubí-Ferrer, L., Svensson, M., Martinson, I., Boza-Serrano, A., Venero, J. L., Nielsen, H. M., et al. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00566-4 · Cited by 278
The implications of different approaches to define AT(N) in Alzheimer disease
Mattsson-Carlgren, N., Leuzy, A., Janelidze, S., Palmqvist, S., Stomrud, E., Strandberg, O., Smith, R., & Hansson, O. (2020) · Neurology · doi:10.1212/wnl.0000000000009485 · Cited by 114
“, [(18)F]FDGPET and novel CSF measures for tau and neurodegeneration).(36,37)”
MethodSelf-citationCerebrospinal fluid tau fragment correlates with tau PET: a candidate biomarker for tangle pathology
Blennow, K., Chen, C., Cicognola, C., Wildsmith, K. R., Manser, P. T., Bohorquez, S. M. S., Zhang, Z., Xie, B., Peng, J., Hansson, O., et al. (2020) · Brain · doi:10.1093/brain/awz346 · Cited by 105
Self-citationChen, G., Kang, S. S., Wang, Z., Ahn, E. H., Xia, Y., Liu, X., Sandoval, I. M., Manfredsson, F. P., Zhang, Z., & Ye, K. (2021) · Science Advances · doi:10.1126/sciadv.abe4499 · Cited by 44
Self-citation
Metadata
- Authors
- Leuzy, A., Cicognola, C., Chiotis, K., Saint-Aubert, L., Lemoine, L., Andreasen, N., Zetterberg, H., Ye, K., Blennow, K., Höglund, K., & Nordberg, A.
- Venue
- European Journal of Nuclear Medicine and Molecular Imaging
- Published
- 2019-01-04
- Volume
- 46
- Issue
- 5
- Pages
- 1152-1163
- ISSN
- 1619-7070 (ISSN-L)
- 1619-7089
- OpenAlex
- W2908411107
- Cited by
- 45
- References
- 22
- FWCI
- 5.27
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.